PDF herunterladen
Aktuelle Urol 2010; 41(3): 193-196
DOI: 10.1055/s-0030-1247395
Konsensuskonferenz

© Georg Thieme Verlag Stuttgart ˙ New York

Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms

Interdisciplinary Recommendations for the Treatment of Metastatic Renal Cell CarcinomaK. Miller1 , L. Bergmann2 , P. Albers3 , J. Gschwend4 , E. Jäger5 , U. Keilholz6
  • 1Klinik für Urologie, Charité – Universitätsmedizin Berlin
  • 2Medizinische Klinik II, J. W. Goethe-Universität Frankfurt / Main
  • 3Klinik für Urologie Universitätsklinikum Düsseldorf
  • 4Urologische Klinik und Poliklinik der Technischen Universität München Klinikum rechts der Isar
  • 5Medizinische Klinik II, Krankenhaus Nordwest, Frankfurt / Main
  • 6Medizinische Klinik III, Charité – Universitätsmedizin Berlin
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Mai 2010 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Mit der Einführung zielgerichteter Substanzen hat die Therapie des metastasierten Nierenzellkarzinoms einen Paradigmenwechsel erfahren: Der Einsatz von Zytokinen als langjährige Standardtherapie rückte in den Hintergrund, neue Medikamente wie Sunitinib, Sorafenib, Bevacizumab und Temsirolimus haben sich als Behandlungsstandard etabliert. Seit Mitte 2009 werden diese Substanzen durch Everolimus ergänzt. Welche Kriterien beim Einsatz dieser Medikamente zu berücksichtigen sind und welche Fragen auf Basis der aktuellen Studienlage noch unbeantwortet bleiben, war Gegenstand einer Konsensuskonferenz. Das interdisziplinäre Board knüpfte an Therapieempfehlungen aus dem Jahr 2008 an [1]. Das Ergebnis der Diskussion wird hier in Form von Thesen zusammengefasst.

Abstract

With the introduction of targeted therapies, a ­paradigm shift for the treatment of metastatic renal cell carcinoma has taken place. The use of cytokines as the long-standing standard therapy has declined. New compounds like sunitinib, ­sorafenib, bevacizumab and temsirolimus have become established as new therapeutic standards. Since mid-2009, these substances have been complemented by everolimus. An interdisciplinary consensus conference was held to discuss what criteria to consider when using these drugs (treatment sequence) and what questions remain unanswered based on the current study situation (open questions). Results from the 2008 confer­ence provided the basis for the 2009 meeting. The results of the 2009 conference are presented as short theses.

Schlüsselwörter

Nierenzellkarzinom - medikamentöse Therapie - zielgerichtete Therapie

Key words

renal cell cancer - medical treatment - targeted therapy

Literatur

  • 1 Miller K, Bergmann L, Jäger E et al. Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms.  Aktuel Urol. 2009;  40 27-30
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Bukowski R M, Negrier S, Elson P et al. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group.  Clin Cancer Res. 2004;  10 6310-6314
    CrossrefPubMedGoogle Scholar
  • 3 Coppin C, Porzsolt F, Kumpf J et al. Immunotherapy for advanced renal cell cancer. Cochrane Database SystRev 2005; (1): CD001425
    PubMedGoogle Scholar
  • 4 Motzer R J, Bacik J, Murphy B A et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.  J Clin Oncol. 2002;  20 289-296
    CrossrefPubMedGoogle Scholar
  • 5 Motzer R J, Hutson T E, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cellcarcinoma.  N Engl J Med. 2007;  356 115-124
    CrossrefPubMedGoogle Scholar
  • 6 Motzer R J et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2009;  27 3584-3590
    CrossrefPubMedGoogle Scholar
  • 7 Escudier B, Koralwski P, Pluzanska A AVOREN ­investigators et al., on behalf of the. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab / interferon-α2 a vs placebo / interferon-α2 a as first-line therapy in metastatic renal cell carcinoma.  J Clin Oncol. 2007;  25 3
    CrossrefPubMedGoogle Scholar
  • 8 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.  N Engl J Med. 2007;  356 2271-2281
    CrossrefPubMedGoogle Scholar
  • 9 Motzer R J, Michaelson M D, Hutson T E et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors.  Eur J Cancer. 2007;  5 301s ,  Abstract 4509
    PubMedGoogle Scholar
  • 10 Escudier B, Eisen T, Stadler W M et al. Sorafenib in advanced clear-cell renal-cell carcinoma.  N Engl J Med. 2007;  356 125-134
    CrossrefPubMedGoogle Scholar
  • 11 Motzer R, Escudier B, Oudard S et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: Results from a randomized, double-blind, multicenter Phase-III study.  J Clin Oncol. 2008;  26 ,  (May 20 suppl; abstr LBA5026)
    PubMedGoogle Scholar
  • 12 Sternberg C, Davis I D, Mardiak J et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial.  J Clin Oncol. 2010;  38 1061-1068
    PubMedGoogle Scholar
  • 13 NCT00720941. (www.clinicaltrials.gov)
    Google Scholar
  • 14 Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group(DGCIN).  J Clin Oncol. 2004;  22 1188-1194
    CrossrefPubMedGoogle Scholar
  • 15 McDermott D F, Regan M M, Clark J I et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2005;  23 133-141
    CrossrefPubMedGoogle Scholar
  • 16 Motzer R J, Michaelson M D, Redman B G et al. Activity of SU11248, a multi­targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with meta­static ­renal cell carcinoma.  J Clin Oncol. 2006;  24 16-24
    CrossrefPubMedGoogle Scholar
  • 17 Motzer R J, Rini B I, Bukowski R M et al. Sunitinib in patients with metastatic renal cell carcinoma.  Jama. 2006;  295 2516-2524
    CrossrefPubMedGoogle Scholar
  • 18 Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie.  N Engl J Med. 1998;  338 1272-1278
    CrossrefPubMedGoogle Scholar
  • 19 Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.  J Clin Oncol. 1999;  17 2859-2867
    PubMedGoogle Scholar
  • 20 Ratain M J, Eisen T, Stadler W M et al. Phase II placebo-controlled randomized discontinuation trial of Sorafenib in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2006;  24 2505-2512
    CrossrefPubMedGoogle Scholar
  • 21 Yang J C, Haworth L, Sherry R M et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for meta-static renal cancer.  N Engl J Med. 2003;  349 427-434
    CrossrefPubMedGoogle Scholar
  • 22 Beck J, Bajetta E, Escudier B et al. A large open-label non-comparative phase III study of the multi-targeted kinase inhibitor Sorafenib in ­European patients with advanced renal cell carcinoma.  ECCO. 2007;  ,  ­Abstract 4506
    PubMedGoogle Scholar
  • 23 Choueiri T K, Plantade A, Elson P et al. Efficacy of sunitinib and Sorafenib in metastatic papillary and chromophobe renal cell carcinoma.  J Clin Oncol. 2008;  26 127-131
    CrossrefPubMedGoogle Scholar
  • 24 Dutcher J P, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated ­patients with advanced renal cell carcinoma (advRCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN).  J Clin Oncol. 2007;  ,  ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18 S (June 20 Supplement): 5033
    PubMedGoogle Scholar
  • 25 Gore M E et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expandedaccess trial.  Lancet Oncol. 2009;  10 757-763
    CrossrefPubMedGoogle Scholar
  • 26 NCT00979966. (www.clinicaltrials.gov)
    Google Scholar
  • 27 Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.  Lancet. 2007;  370 2103-2111
    CrossrefPubMedGoogle Scholar
  • 28 Wyeth Pharma GmbH .Torisel®. Januar 2010
    PubMedGoogle Scholar
  • 29 Bayer Schering Pharma AG .Nexavar® 200 mg Filmtabletten. November 2009
    PubMedGoogle Scholar
  • 30 Pfizer Ltd .SUTENT® 12,5 / 25 / 37,5 / 50 mg Hartkapseln. August 2009
    PubMedGoogle Scholar
  • 31 Roche Pharma AG .Roferon®-A18 Mio. I. E. / 0,6 ml Patrone mit Injek­tions­lösung. Januar 2009
    PubMedGoogle Scholar
  • 32 Roche Registration Ltd .Avastin® 25 mg / ml Konzentrat. Januar 2010
    PubMedGoogle Scholar
  • 33 Bukowski R M, Eisen T, Szczylik W M et al. Final results of the randomized phase III trial of Sorafenib in advanced renal cell carcinoma: Sur­viv­al and biomarker analysis.  ASCO. 2007;  , Abstract 5023 J Clin Oncology 2007 ASCOAnnual Meeting Proceedings Part I. Vol 25, No. 18 S (June 20 Supplement), 2007: 5023
    PubMedGoogle Scholar
  • 34 George D J, Michaelson M D, Rosenberg J E et al. Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC).  ECCO. 2007;  ,  Abstract 4517 European Journal of Cancer Supplements, Vol 5 No 4, Page 303
    PubMedGoogle Scholar
  • 35 Rini B I, Hutson T E, Elson P et al. Phase II Study of Sorafenib in patients with mRCC refractory to Sunitinib or Bevacizumab.  ASCO GU. 2008;  ,  ­Abstract 3461
    PubMedGoogle Scholar
  • 36 Tamaskar I, Garcia J A et al. Antitumor effects of sunitinib or Sorafenib in patients with metastatic renal cell carcinoma who received prior anti­angiogenic therapy.  J Urol. 2008;  179 81-86
    PubMedGoogle Scholar
  • 37 Flanigan R C, Mickisch G, Sylvester R et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.  J Urol. 2004;  171 1071-1076
    CrossrefPubMedGoogle Scholar
  • 38 Baccala Jr A, Hedgepath R, Kaouk J et al. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.  Int J Urol. 2007;  14 1095-1097
    CrossrefPubMedGoogle Scholar
  • 39 Heng D Y, Rini B Y, Garci J et al. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.  Clin Genitourin Cancer. 2007;  5 446-451
    CrossrefPubMedGoogle Scholar
  • 40 Karakiewicz P I, Suardi N, Jeldres C et al. Neoadjuvant sutent induc­tion therapy may effectively down-stage renal cell carcinoma atrial ­thrombi.  Eur Urol. 2008;  53 845-848
    CrossrefPubMedGoogle Scholar
  • 41 Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with inter­leukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumournephrectomy:results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).  Br J Cancer. 2005;  92 843-846
    CrossrefPubMedGoogle Scholar

1 Memorial Sloan-Kettering Cancer Center (MSKCC) Risikofaktoren:
– niedriges Hämoglobin (< Normwert)
– erhöhtes korrigiertes Kalzium (> 10 mg / dl)
– erhöhte Laktatdehydrogenase (> 1,5-facher Normwert)
– schlechter Performance-Status (Karnofsky < 80 %)
– Zeit von der Erstdiagnose bis zur Behandlung < 1 Jahr
MSKCC-Risikogruppen zur Abschätzung des Progressionsrisikos:
– Risikogruppe 1 (niedriges Risiko) = 0 Risikofaktoren
– Risikogruppe 2 (mittleres Risiko) = 1 oder 2 Risikofaktoren
– Risikogruppe 3 (hohes Risiko) = 3–5 Risikofaktoren

Prof. Dr. med. K. Miller

Charité · Urologische Klinik und Hochschulambulanz

Hindenburgdamm 30

12200 Berlin

eMail: Kurt.miller@charite.de